Pulmonary outcome prediction (POP) tools for cystic fibrosis patients

Donald R. Vandevanter, Jeffrey S. Wagener, David J. Pasta, Eric Elkin, Joan R. Jacobs, Wayne J Morgan, Michael W. Konstan

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Rationale Loss of lung function in patients with cystic fibrosis (CF) is associated with increased mortality and varies between individuals and over time. Predicting this decline could improve patient management. Objectives To develop simple pulmonary outcome prediction (POP) tools to estimate lung function at age 6 in patients aged 2-5 years (POP2-5) and lung function change over a 4-year period in patients aged 6-17 years (POP 6-17). Methods Analyses were conducted using patients from the Epidemiologic Study of CF (ESCF). To be included in any analysis, patients had to have 1 year of clinical history recorded in ESCF prior to a clinically stable routine Index Clinic Visit (ICV). In addition to this criterion, for the POP2-5 tool patients had to be between 2 and 5 years old at ICV and have a second clinically stable visit with spirometric measures at age 6. For the POP6-17 tool, patients had to be between the ages of 6 and 17 years old at an ICV that included spirometric measures and had to have a second clinically stable visit with spirometric measures from 3 to 5 years after ICV. All patients enrolled in ESCF who met these inclusion criteria were studied. POP2-5 and POP6-17 populations were further divided into development groups (with ICV before January 1, 1998) and validation groups (with ICV after that date). Development groups were used to model forced expiratory volume in 1sec (FEV1) percent predicted at age 6 years (for POP 2-5) and annualized FEV1% predicted change from ICV to the second visit (for POP6-17) by multivariable linear regression using age, sex, weight-for-age percentile, cough, sputum production, clubbing, crackles, wheeze, sinusitis, number of exacerbations requiring intravenous antibiotics in the past year, elevated liver enzymes, pancreatic enzyme use, and respiratory tract culture status, plus height-for-age percentile (POP 2-5) and index FEV1 (POP6-17). Integer-based POP2-5 and POP6-17 tools created from selected variables were evaluated by Pearson correlation and then prospectively validated with separate data collected later from ESCF patients with ICV after January 1, 1998. Main Results POP2-5 and POP6-17 development groups included 2,709 and 6,113 patients and validation groups included 3,458 and 7,086 patients, respectively. Variables retained were weight-for-age percentile, clubbing, crackles, wheeze, number of exacerbations, and Pseudomonas aeruginosa culture status (both tools), daily cough (POP2-5), and age, sex, and index FEV1% predicted (POP6-17). Correlation coefficients for POP2-5 and POP6-17 tools prospectively applied to validation groups were +0.32 and +0.37, respectively. Conclusions These simple integer-based POP algorithms employ variables available at clinic visits and can be used to predict the probability of different future pulmonary outcomes for individual patients and patient populations.

Original languageEnglish (US)
Pages (from-to)1156-1166
Number of pages11
JournalPediatric Pulmonology
Volume45
Issue number12
DOIs
StatePublished - Dec 2010

Fingerprint

Cystic Fibrosis
Ambulatory Care
Lung
Forced Expiratory Volume
Epidemiologic Studies
Respiratory Sounds
Cough
Weights and Measures
Sinusitis
Enzymes
Sputum
Respiratory System
Pseudomonas aeruginosa
Population
Linear Models
Anti-Bacterial Agents

Keywords

  • decline
  • epidemiology
  • predictive variables
  • pulmonary function outcome

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Cite this

Vandevanter, D. R., Wagener, J. S., Pasta, D. J., Elkin, E., Jacobs, J. R., Morgan, W. J., & Konstan, M. W. (2010). Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. Pediatric Pulmonology, 45(12), 1156-1166. https://doi.org/10.1002/ppul.21311

Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. / Vandevanter, Donald R.; Wagener, Jeffrey S.; Pasta, David J.; Elkin, Eric; Jacobs, Joan R.; Morgan, Wayne J; Konstan, Michael W.

In: Pediatric Pulmonology, Vol. 45, No. 12, 12.2010, p. 1156-1166.

Research output: Contribution to journalArticle

Vandevanter, DR, Wagener, JS, Pasta, DJ, Elkin, E, Jacobs, JR, Morgan, WJ & Konstan, MW 2010, 'Pulmonary outcome prediction (POP) tools for cystic fibrosis patients', Pediatric Pulmonology, vol. 45, no. 12, pp. 1156-1166. https://doi.org/10.1002/ppul.21311
Vandevanter DR, Wagener JS, Pasta DJ, Elkin E, Jacobs JR, Morgan WJ et al. Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. Pediatric Pulmonology. 2010 Dec;45(12):1156-1166. https://doi.org/10.1002/ppul.21311
Vandevanter, Donald R. ; Wagener, Jeffrey S. ; Pasta, David J. ; Elkin, Eric ; Jacobs, Joan R. ; Morgan, Wayne J ; Konstan, Michael W. / Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. In: Pediatric Pulmonology. 2010 ; Vol. 45, No. 12. pp. 1156-1166.
@article{a023355c87094d61b732a147e2c7994b,
title = "Pulmonary outcome prediction (POP) tools for cystic fibrosis patients",
abstract = "Rationale Loss of lung function in patients with cystic fibrosis (CF) is associated with increased mortality and varies between individuals and over time. Predicting this decline could improve patient management. Objectives To develop simple pulmonary outcome prediction (POP) tools to estimate lung function at age 6 in patients aged 2-5 years (POP2-5) and lung function change over a 4-year period in patients aged 6-17 years (POP 6-17). Methods Analyses were conducted using patients from the Epidemiologic Study of CF (ESCF). To be included in any analysis, patients had to have 1 year of clinical history recorded in ESCF prior to a clinically stable routine Index Clinic Visit (ICV). In addition to this criterion, for the POP2-5 tool patients had to be between 2 and 5 years old at ICV and have a second clinically stable visit with spirometric measures at age 6. For the POP6-17 tool, patients had to be between the ages of 6 and 17 years old at an ICV that included spirometric measures and had to have a second clinically stable visit with spirometric measures from 3 to 5 years after ICV. All patients enrolled in ESCF who met these inclusion criteria were studied. POP2-5 and POP6-17 populations were further divided into development groups (with ICV before January 1, 1998) and validation groups (with ICV after that date). Development groups were used to model forced expiratory volume in 1sec (FEV1) percent predicted at age 6 years (for POP 2-5) and annualized FEV1{\%} predicted change from ICV to the second visit (for POP6-17) by multivariable linear regression using age, sex, weight-for-age percentile, cough, sputum production, clubbing, crackles, wheeze, sinusitis, number of exacerbations requiring intravenous antibiotics in the past year, elevated liver enzymes, pancreatic enzyme use, and respiratory tract culture status, plus height-for-age percentile (POP 2-5) and index FEV1 (POP6-17). Integer-based POP2-5 and POP6-17 tools created from selected variables were evaluated by Pearson correlation and then prospectively validated with separate data collected later from ESCF patients with ICV after January 1, 1998. Main Results POP2-5 and POP6-17 development groups included 2,709 and 6,113 patients and validation groups included 3,458 and 7,086 patients, respectively. Variables retained were weight-for-age percentile, clubbing, crackles, wheeze, number of exacerbations, and Pseudomonas aeruginosa culture status (both tools), daily cough (POP2-5), and age, sex, and index FEV1{\%} predicted (POP6-17). Correlation coefficients for POP2-5 and POP6-17 tools prospectively applied to validation groups were +0.32 and +0.37, respectively. Conclusions These simple integer-based POP algorithms employ variables available at clinic visits and can be used to predict the probability of different future pulmonary outcomes for individual patients and patient populations.",
keywords = "decline, epidemiology, predictive variables, pulmonary function outcome",
author = "Vandevanter, {Donald R.} and Wagener, {Jeffrey S.} and Pasta, {David J.} and Eric Elkin and Jacobs, {Joan R.} and Morgan, {Wayne J} and Konstan, {Michael W.}",
year = "2010",
month = "12",
doi = "10.1002/ppul.21311",
language = "English (US)",
volume = "45",
pages = "1156--1166",
journal = "Pediatric Pulmonology",
issn = "8755-6863",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Pulmonary outcome prediction (POP) tools for cystic fibrosis patients

AU - Vandevanter, Donald R.

AU - Wagener, Jeffrey S.

AU - Pasta, David J.

AU - Elkin, Eric

AU - Jacobs, Joan R.

AU - Morgan, Wayne J

AU - Konstan, Michael W.

PY - 2010/12

Y1 - 2010/12

N2 - Rationale Loss of lung function in patients with cystic fibrosis (CF) is associated with increased mortality and varies between individuals and over time. Predicting this decline could improve patient management. Objectives To develop simple pulmonary outcome prediction (POP) tools to estimate lung function at age 6 in patients aged 2-5 years (POP2-5) and lung function change over a 4-year period in patients aged 6-17 years (POP 6-17). Methods Analyses were conducted using patients from the Epidemiologic Study of CF (ESCF). To be included in any analysis, patients had to have 1 year of clinical history recorded in ESCF prior to a clinically stable routine Index Clinic Visit (ICV). In addition to this criterion, for the POP2-5 tool patients had to be between 2 and 5 years old at ICV and have a second clinically stable visit with spirometric measures at age 6. For the POP6-17 tool, patients had to be between the ages of 6 and 17 years old at an ICV that included spirometric measures and had to have a second clinically stable visit with spirometric measures from 3 to 5 years after ICV. All patients enrolled in ESCF who met these inclusion criteria were studied. POP2-5 and POP6-17 populations were further divided into development groups (with ICV before January 1, 1998) and validation groups (with ICV after that date). Development groups were used to model forced expiratory volume in 1sec (FEV1) percent predicted at age 6 years (for POP 2-5) and annualized FEV1% predicted change from ICV to the second visit (for POP6-17) by multivariable linear regression using age, sex, weight-for-age percentile, cough, sputum production, clubbing, crackles, wheeze, sinusitis, number of exacerbations requiring intravenous antibiotics in the past year, elevated liver enzymes, pancreatic enzyme use, and respiratory tract culture status, plus height-for-age percentile (POP 2-5) and index FEV1 (POP6-17). Integer-based POP2-5 and POP6-17 tools created from selected variables were evaluated by Pearson correlation and then prospectively validated with separate data collected later from ESCF patients with ICV after January 1, 1998. Main Results POP2-5 and POP6-17 development groups included 2,709 and 6,113 patients and validation groups included 3,458 and 7,086 patients, respectively. Variables retained were weight-for-age percentile, clubbing, crackles, wheeze, number of exacerbations, and Pseudomonas aeruginosa culture status (both tools), daily cough (POP2-5), and age, sex, and index FEV1% predicted (POP6-17). Correlation coefficients for POP2-5 and POP6-17 tools prospectively applied to validation groups were +0.32 and +0.37, respectively. Conclusions These simple integer-based POP algorithms employ variables available at clinic visits and can be used to predict the probability of different future pulmonary outcomes for individual patients and patient populations.

AB - Rationale Loss of lung function in patients with cystic fibrosis (CF) is associated with increased mortality and varies between individuals and over time. Predicting this decline could improve patient management. Objectives To develop simple pulmonary outcome prediction (POP) tools to estimate lung function at age 6 in patients aged 2-5 years (POP2-5) and lung function change over a 4-year period in patients aged 6-17 years (POP 6-17). Methods Analyses were conducted using patients from the Epidemiologic Study of CF (ESCF). To be included in any analysis, patients had to have 1 year of clinical history recorded in ESCF prior to a clinically stable routine Index Clinic Visit (ICV). In addition to this criterion, for the POP2-5 tool patients had to be between 2 and 5 years old at ICV and have a second clinically stable visit with spirometric measures at age 6. For the POP6-17 tool, patients had to be between the ages of 6 and 17 years old at an ICV that included spirometric measures and had to have a second clinically stable visit with spirometric measures from 3 to 5 years after ICV. All patients enrolled in ESCF who met these inclusion criteria were studied. POP2-5 and POP6-17 populations were further divided into development groups (with ICV before January 1, 1998) and validation groups (with ICV after that date). Development groups were used to model forced expiratory volume in 1sec (FEV1) percent predicted at age 6 years (for POP 2-5) and annualized FEV1% predicted change from ICV to the second visit (for POP6-17) by multivariable linear regression using age, sex, weight-for-age percentile, cough, sputum production, clubbing, crackles, wheeze, sinusitis, number of exacerbations requiring intravenous antibiotics in the past year, elevated liver enzymes, pancreatic enzyme use, and respiratory tract culture status, plus height-for-age percentile (POP 2-5) and index FEV1 (POP6-17). Integer-based POP2-5 and POP6-17 tools created from selected variables were evaluated by Pearson correlation and then prospectively validated with separate data collected later from ESCF patients with ICV after January 1, 1998. Main Results POP2-5 and POP6-17 development groups included 2,709 and 6,113 patients and validation groups included 3,458 and 7,086 patients, respectively. Variables retained were weight-for-age percentile, clubbing, crackles, wheeze, number of exacerbations, and Pseudomonas aeruginosa culture status (both tools), daily cough (POP2-5), and age, sex, and index FEV1% predicted (POP6-17). Correlation coefficients for POP2-5 and POP6-17 tools prospectively applied to validation groups were +0.32 and +0.37, respectively. Conclusions These simple integer-based POP algorithms employ variables available at clinic visits and can be used to predict the probability of different future pulmonary outcomes for individual patients and patient populations.

KW - decline

KW - epidemiology

KW - predictive variables

KW - pulmonary function outcome

UR - http://www.scopus.com/inward/record.url?scp=78649662363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649662363&partnerID=8YFLogxK

U2 - 10.1002/ppul.21311

DO - 10.1002/ppul.21311

M3 - Article

C2 - 20717915

AN - SCOPUS:78649662363

VL - 45

SP - 1156

EP - 1166

JO - Pediatric Pulmonology

JF - Pediatric Pulmonology

SN - 8755-6863

IS - 12

ER -